Literature DB >> 9834410

Glucagon-like peptide 2 is a potent growth factor for small intestine and colon.

D A Litvak1, M R Hellmich, B M Evers, N A Banker, C M Townsend.   

Abstract

Factors that stimulate gut mucosal proliferation may be beneficial during periods of gut disuse or atrophy. Recently glucagon-like peptide 2 (GLP-2) has been shown to stimulate small bowel growth. The purpose of our study was to compare the trophic effects of GLP-2 with those of neurotensin (NT), a potent gut trophic factor. Mice were randomized to receive either GLP-2, NT, or saline solution (control) for 10 days. The mice were killed on day 11, at which time the jejunum, ileum, and colon were removed, weighed, and DNA and protein content measured. Mice treated with GLP-2 showed a significant increase in the weight of the jejunum, ileum, and colon compared to both control and NT-treated mice. DNA content, a marker of cellular hyperplasia, was significantly increased in the small bowel and colon by treatment with GLP-2 and NT compared to control tissues. Small intestinal protein content, an indicator of cellular hypertrophy, was significantly increased by GLP-2 compared to both NT and control; protein content of the colon was greater in each of the treatment groups compared with control mice. We have demonstrated, for the first time, that GLP-2 stimulates colonic growth. In addition, GLP-2 is a potent trophic factor of normal small intestine with proliferative effects that are equal to or greater than those of NT. Administration of GLP-2 may be useful clinically to enhance small intestinal regeneration and adaptation during periods of disease and in the early phases of the short bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834410     DOI: 10.1016/s1091-255x(98)80005-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  23 in total

1.  Neurotensin augments intestinal regeneration after small bowel resection in rats.

Authors:  M Izukura; B M Evers; D Parekh; K Yoshinaga; T Uchida; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1992-05       Impact factor: 12.969

Review 2.  Molecular biology of gastrointestinal peptides and growth factors: relevance to intestinal adaptation.

Authors:  P K Lund; M H Ulshen; D B Rountree; S E Selub; A M Buchan
Journal:  Digestion       Date:  1990       Impact factor: 3.216

Review 3.  Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles.

Authors:  J M Conlon
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 4.  Nutrition, operations, and intestinal adaptation.

Authors:  J B Bristol; R C Williamson
Journal:  JPEN J Parenter Enteral Nutr       Date:  1988 May-Jun       Impact factor: 4.016

5.  Functional compensation after small-bowel resection in man. Demonstration by direct measurement.

Authors:  R H Dowling; C C Booth
Journal:  Lancet       Date:  1966-07-16       Impact factor: 79.321

Review 6.  Short bowel syndrome: metabolic and surgical management.

Authors:  L K Shanbhogue; J C Molenaar
Journal:  Br J Surg       Date:  1994-04       Impact factor: 6.939

7.  Intestinal peptide YY: ontogeny of gene expression in rat bowel and trophic actions on rat and mouse bowel.

Authors:  G Gomez; T Zhang; S Rajaraman; K N Thakore; N Yanaihara; C M Townsend; J C Thompson; G H Greeley
Journal:  Am J Physiol       Date:  1995-01

8.  A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet.

Authors:  T A Byrne; R L Persinger; L S Young; T R Ziegler; D W Wilmore
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

9.  Neurotensin stimulates growth of small intestine in rats.

Authors:  J G Wood; H D Hoang; L J Bussjaeger; T E Solomon
Journal:  Am J Physiol       Date:  1988-12

10.  Effect of aging on neurotensin-stimulated growth of rat small intestine.

Authors:  B M Evers; M Izukura; S Rajaraman; D Parekh; K Thakore; K Yoshinaga; T Uchida; C M Townsend; J C Thompson
Journal:  Am J Physiol       Date:  1994-08
View more
  19 in total

1.  Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Authors:  Bharati Kochar; Millie D Long; Edward Shelton; Lorraine Young; Francis A Farraye; Vijay Yajnik; Hans Herfarth
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

Review 2.  Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Authors:  Hubert Zatorski; Maciej Sałaga; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-29       Impact factor: 3.000

3.  Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats.

Authors:  W Ren; J Wu; L Li; Y Lu; Y Shao; Y Qi; B Xu; Y He; Y Hu
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

4.  Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro.

Authors:  Jasleen Jasleen; Stanley W Ashley; Naoshi Shimoda; Michael J Zinner; Edward E Whang
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

Review 5.  Advances in short bowel syndrome: an updated review.

Authors:  Igor Sukhotnik; Arnold G Coran; Alexander Kramer; Eitan Shiloni; Jorge G Mogilner
Journal:  Pediatr Surg Int       Date:  2005-11-03       Impact factor: 1.827

6.  Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin.

Authors:  D A Litvak; B M Evers; M R Hellmich; C M Townsend
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

7.  Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis.

Authors:  Seung-Jun Lee; Jennifer Lee; Karen K Li; Dianne Holland; Heather Maughan; David S Guttman; Bernardo Yusta; Daniel J Drucker
Journal:  Endocrinology       Date:  2012-01-17       Impact factor: 4.736

8.  Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.

Authors:  D G Munroe; A K Gupta; F Kooshesh; T B Vyas; G Rizkalla; H Wang; L Demchyshyn; Z J Yang; R K Kamboj; H Chen; K McCallum; M Sumner-Smith; D J Drucker; A Crivici
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Novel insight into the distribution of L-cells in the rat intestinal tract.

Authors:  Carl Frederik Hansen; Niels Vrang; Per Torp Sangild; Jacob Jelsing
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

10.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.